Army issues Request for Information on nerve agent antidote administered via autoinjector

The U.S. Army released on Friday a Request for Information regarding the manufacturing capability for the development of a nerve agent antidote administered via autoinjector.

The Request for Information seeks data on a combination nerve agent antidote including atropine and 2-pralidoxime antidotes in a single intramuscular autoinjector, to be administered by an authorized military service member. Atropine and 2-PAM are already used in combination with a pretreatment, pyridostigmine bromide and an anticonvulsant.

The Army asked that all recommended delivery platforms and antidotes be operationally stable in extreme temperatures. The ideal storage conditions are identical to Antidote Treatment Nerve Agent Autoinjector recommended conditions, which include stable storage at temperatures from 50 to 86 degrees Fahrenheit for up to five years. The Army asked that any advances capable of reducing the burden of storing the vaccines be taken.

The Army requested any organization capable of providing this information do so. The information requested is for planning purposes only and will not result in a binding contract or payment.

All submissions must include both a description of the company's proposed platform for delivery of the drug and information on the company's experience and success with the U.S. Food and Drug Administration. All submissions are due by November 2, 2013.